Insulin lispro protamine suspension in the treatment of patients with type 1 and type 2 diabetes mellitus: a systematic review of published data

Bibliography

• DeFelippis MR, Bakaysa DL, Bell MA, Preparation and characterization of a cocrystalline suspension of [LysB28, ProB29]-human insulin analogue. J Pharm Sci 1998;87:170-6
   PubMed Web of Science ®Google Scholar
• Garber AJ. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs 2006;66(1):31-49
   PubMed Web of Science ®Google Scholar
• Buse JB, Wolffenbuttel BH, Herman WH, Durability of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care 2009;32(6):1007-13
   PubMed Web of Science ®Google Scholar
• Arakaki RF, Blevins TC, Liljenquist DR, Efficacy and safety of insulin lispro protamine suspension (ILPS) versus insulin glargine (G) added to oral Antihyperglycaemic medications and exenatide in patients with type 2 diabetes. EASD; 2010
   Google Scholar
• Koivisto V, Cleall S, Pontiroli AE, Giugliano D. Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal-bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open-label trial. Diabetes Obes Metab 2011;13:1149-57
   PubMed Web of Science ®Google Scholar
• Janssen MM, Casteleijn S, Deville W, Nighttime insulin kinetics and glycemic control in type 1 diabetes patients following administration of an intermediate-acting lispro preparation. Diabetes Care 1997;20(12):1870-3
   PubMed Web of Science ®Google Scholar
• Hompesch M, Ocheltree SM, Wondmagegnehu ET, Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. Curr Med Res Opin 2009;25(11):2679-87
   PubMed Web of Science ®Google Scholar
• Ocheltree SM, Hompesch M, Wondmagegnehu ET, Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. Eur J Endocrinol 2010;163(2):217-23
   PubMed Web of Science ®Google Scholar
• Esposito K, Ciotola M, Maiorino MI, Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. Ann Intern Med 2008;149(8):531-9
   PubMed Web of Science ®Google Scholar
• Strojek K, Shi C, Carey MA, Jacober SJ. Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens: a randomized trial. Diabetes Obes Metab 2010;12(10):916-22
   PubMed Web of Science ®Google Scholar
• Chacra AR, Kipnes M, Ilag LL, Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 diabetes. Diabetes Med 2010;27(5):563-9
   PubMed Web of Science ®Google Scholar
• Fogelfeld L, Dharmalingam M, Robling K, A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes. Diabetes Med 2010;27:181-8
   PubMed Web of Science ®Google Scholar
• Citro G, Lorusso B, Rossi A, Insulin lispro protamine suspension in intensive insulin treatment: an Italian observational study. Curr Med Res Opin 2009;25(9):2259-65
   PubMed Web of Science ®Google Scholar
• Heise T, Weyer C, Serwas A, Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care 1998;21(5):800-3
   PubMed Web of Science ®Google Scholar
• Roach P, Woodworth J, Gudat U, A 75% insulin lispro/25% NPL mixture provides a longer duration of insulin activity compared with insulin lispro alone in patients with Type 1 diabetes. Diabetes Med 2003;20(11):946-52
   PubMed Web of Science ®Google Scholar
• Koivisto VA, Tuominen JA, Ebeling P. Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients. Diabetes Care 1999;22(3):459-62
   PubMed Web of Science ®Google Scholar
• Malone JK, Woodworth JR, Arora V, Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus. Clin Ther 2000;22(2):222-30
   PubMed Web of Science ®Google Scholar
• Malone JK, Yang H, Woodworth JR, Humalog Mix25 offers better mealtime glycemic control in patients with type 1 or type 2 diabetes. Diabetes Metab 2000;26(6):481-7
   PubMed Web of Science ®Google Scholar
• Schwartz S, Zagar AJ, Althouse SK, A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus. Clin Ther 2006;28(10):1649-57
   PubMed Web of Science ®Google Scholar
• Roach P, Yue L, Arora V. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group. Diabetes Care 1999;22(8):1258-61
   PubMed Web of Science ®Google Scholar
• Roach P, Trautmann M, Arora V, Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Mix50 Study Group. Clin Ther 1999;21(3):523-34
   PubMed Web of Science ®Google Scholar
• Roach P, Strack T, Arora V, Zhao Z. Improved glycaemic control with the use of self-prepared mixtures of insulin lispro and insulin lispro protamine suspension in patients with types 1 and 2 diabetes. Int J Clin Pract 2001;55(3):177-82
   PubMed Web of Science ®Google Scholar
• Herz M, Profozic V, Arora V, Effects of a fixed mixture of 25% insulin lispro and 75% NPL on plasma glucose during and after moderate physical exercise in patients with type 2 diabetes. Curr Med Res Opin 2002;18(4):188-93
   PubMed Web of Science ®Google Scholar
• Roach P, Arora V, Campaigne BN, Humalog Mix50 before carbohydrate-rich meals in type 2 diabetes mellitus. Diabetes Obes Metab 2003;5(5):311-16
   PubMed Web of Science ®Google Scholar
• Roach P, Bai S, Charbonnel B, Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus. Clin Ther 2004;26(4):502-10
   PubMed Web of Science ®Google Scholar
• Roach P, Koledova E, Metcalfe S, Glycemic control with Humalog Mix25 in type 2 diabetes inadequately controlled with glyburide. Clin Ther 2001;23(10):1732-44
   PubMed Web of Science ®Google Scholar
• Malone JK, Beattie SD, Campaigne BN, Therapy after single oral agent failure: adding a second oral agent or an insulin mixture? Diabetes Res Clin Pract 2003;62(3):187-95
   PubMed Web of Science ®Google Scholar
• Jacober SJ, Scism-Bacon JL, Zagar AJ. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naive patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes Obes Metab 2006;8(4):448-55
   PubMed Web of Science ®Google Scholar
• Malone JK, Kerr LF, Campaigne BN, Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004;26(12):2034-44
   PubMed Web of Science ®Google Scholar
• Malone JK, Bai S, Campaigne BN, Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes. Diabet Med 2005;22(4):374-81
   PubMed Web of Science ®Google Scholar
• Roach P, Malone JK. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes. Diabetes Med 2006;23(7):743-9
   PubMed Web of Science ®Google Scholar
• Robbins DC, Beisswenger PJ, Ceriello A, Mealtime 50/50 basal plus prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Clin Ther 2007;29(11):2349-64
   PubMed Web of Science ®Google Scholar
• Gao Y, Li G, Li Y, Postprandial blood glucose response to a standard test meal in insulin-requiring patients with diabetes treated with insulin lispro mix 50 or human insulin mix 50. Int J Clin Pract 2008;62(9):1344-51
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Ahmann AJ, Colon G, Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008;31(1):20-5
   PubMed Web of Science ®Google Scholar
• Beattie SD, Kerr LN, Jacober SJ, Comparing within-patient glucose variability in analog vs human insulin self-prepared mixture regimens (Insulin Lispro + Insulin Lispro Protamine Suspension vs Regular Human Insulin + NPH). Diabetologia 2007;50(Suppl 1):S396-7
   Google Scholar
• Beisswenger PJ, Brown WV, Ceriello A, Meal-induced increases in C-reactive protein, interleukin-6 and tumour necrosis factor alpha are attenuated by prandial + basal insulin in patients with type 2 diabetes. Diabetes Med 2011;28:1088-95
   PubMed Web of Science ®Google Scholar
• Miser WF, Arakaki R, Jiang H, Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy of the DURABLE trial. Clin Ther 2010;32(5):896-908
   PubMed Web of Science ®Google Scholar
• Ahmann A, Jiang H, Martin S. Hypoglycemia rates with titration of prandial premixed (ILPS/Lispro) or basal bolus (Glargine/Lispro) insulin therapy in patients with type 2 diabetes (T2D). ADA 2008a, Abstract Number: 490-P. Available from: http://professional.diabetes.org/Abstracts_Display.aspx?TYP=1&CID=69799
   Google Scholar
• Ahmann A, Jiang H, Martin S. A comparison of prandial premixed (ILPS/Lispro) vs. basal bolus (Glargine/Lispro) insulin therapy in obese patients with type 2 diabetes (T2D). ADA 2008b, Abstract Number: 2042-PO. Available from: http://professional.diabetes.org/Abstracts_Display.aspx?TYP=1&CID=70800
   Google Scholar
• Martin S, Scism-Bacon J, Jiang H. A specific patient population achieves glycemic control with prandial premixed (Lispro/ILPS) insulin therapy with lower insulin dose and less weight gain than basal bolus therapy. Diabetologia 2008;51(Suppl 1):S393
   Google Scholar
• Colon G, Jiang H, Martin S. Efficacy and safety of prandial premixed (ILPS/Lispro) vs. basal bolus (Glargine/Lispro) insulin therapy in Hispanic and African American patients with type 2 diabetes (T2D). ADA 2008, Abstract Number: 480-P. Available from: http://professional.diabetes.org/Abstracts_Display.aspx?TYP=1&CID=69788
   Google Scholar
• Jiang H, Milicevic Z, Scism-Bacon J, Martin S. Effect of switching from insulin lispro Mix 50 to lispro Mix 25 at the evening meal during prandial premixed (Lispro/ILPS) therapy (PPT) in type 2 diabetes (T2D) patients. Diabetologia 2008;51(Suppl 1):S403
   Google Scholar
• Hirsch IB, Yuan H, Campaigne BN, Tan MH. Impact of prandial plus basal vs basal insulin on glycemic variability in type 2 diabetic patients. Endocr Pract 2009;15(4):343-8
   PubMed Web of Science ®Google Scholar
• Roach P, Woodworth JR. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures. Clin Pharmacokinet 2002;41(13):1043-57
   PubMed Web of Science ®Google Scholar
• Garber AJ, Ligthelm R, Christiansen JS, Liebl A. Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes Obes Metab 2007;9(5):630-9
   PubMed Web of Science ®Google Scholar
• Bonafede MM, Kalsekar A, Pawaskar M, Insulin use and persistence in patients with type 2 diabetes adding mealtime insulin to a basal regimen: a retrospective database analysis. BMC Endocr Disord 2011;11:3
   PubMed Web of Science ®Google Scholar
• Cavalot F, Petrelli A, Traversa M, Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006;91(3):813-19
   PubMed Web of Science ®Google Scholar
• Monnier L, Colette C, Owens DR. Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it? J Diabetes Sci Technol 2008;2(6):1094-100
   PubMedGoogle Scholar